Bristol-Myers Squibb Company (BMY) Announces Merger with Medarex, Inc.
Bristol-Myers Squibb Company and Medarex, Inc. (NASDAQ: MEDX) were excited to announce that the companies have signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb for $16.00 per share in cash. Both companies’ boards of directors have unanimously approved the transaction, with an aggregate purchase price of approximately $2.4 billion. Medarex’s projected $300 million in net cash and marketable securities at closing would be an asset acquired by Bristol-Myers Squibb resulting in an implied purchase price of approximately $2.1 billion. James M. Cornelius, chairman and chief executive officer of Bristol-Myers Squibb, stated, “Medarex’s technology platform,…